Medindia
About ▼ Careers Internship MedBlog Contact us
English (US) ▼
Medindia
LOGIN REGISTER
Advertisement

Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

Monday, January 25, 2010 General News
Advertisement
Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm
Advertisement

KERYX CONTACT:

Lauren Fischer

Director, Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5962

E-mail:  [email protected]

Sponsored Post and Backlink Submission


Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS
Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...
Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short
More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...
Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer
The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...
A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries
Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....
Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close